Dr. Teresa H. Evering, MD

Dr. Evering practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Evering's NPI, 1518057348, was assigned on October 13, 2006. Dr. Evering graduated from Weill Cornell Medicine in 1997. Dr. Evering holds New York license 216587.

Dr. Evering's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Evering's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Evering to 2 more clinical labs, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Evering practices, 3 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Evering's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Evering is board certified in infectious disease by the American Board of Internal Medicine. Dr. Evering is licensed in New York.

CMS data shows 101 Medicare services from Dr. Evering across 2 procedure codes in 2024, for 61 Medicare patients. Medicare paid $8,798 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 61 Medicare patients who saw Dr. Evering in 2024. The largest group is 75 to 84, with 23 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 2.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Evering's median patient age at 47, with 43% women.

In 2024, Dr. Evering wrote 51 Medicare Part D claims. 27% of them were for generic drugs. CMS names the drug for 36 of them, across 2 drugs with 11 or more claims each, at $146,761 in total drug cost. In 2022, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Evering for performance year 2024, reported through an alternative payment model (APM). Dr. Evering accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 40 papers to Dr. Evering, published from 2006 to 2024. 2021 was the busiest year, with 4. The most frequent topics are HIV Infections, HIV-1 and CD4-Positive T-Lymphocytes. Dr. Evering has published most often in Antibiotics (Basel). Dr. Evering's most frequent co-authors are Martin Markowitz, MD, Barry S. Coller, MD and Saurabh Mehandru, MD.

CMS Open Payments shows 2 general payments to Dr. Evering from 2 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 84% of the total. Gilead Sciences, Inc. paid the most, $104. It also lists 5 research payments totaling $673 in 2017.

Dr. Evering graduated from Weill Cornell Medicine in 1997.

Dr. Evering is in network with 15 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.